Page 3


  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie expands its IBD prospects with $250M Celsius deal

    The pharma’s acquisition of Celsius is the latest in a string of deals by major drugmakers hunting anti-inflammatory medicines.

  • An illustration of CRISPR-cas9 gene editing
    Image attribution tooltip
    del Aguila III, Ernesto. (2018). "CRISPR Cas9" [Illustration]. Retrieved from Flickr.
    Image attribution tooltip

    First-of-its-kind Intellia data suggest CRISPR drug could be given more than once

    The findings provide early proof that multiple doses of a gene editing medicine can be safely administered with additive effects, overcoming a key constraint of the complex therapies.  

  • A photo of Bluebird bio employees in a laboratory.
    Image attribution tooltip
    Courtesy of Bluebird bio
    Image attribution tooltip

    2seventy slims down with sale of hemophilia assets to Novo

    Novo will pay $38 million in cash under the deal, which will also see 2seventy employees working on the program transfer to the Danish drugmaker.

  • Two prescription drug cartons are seen standing vertically on end, bearing the word Wegovy.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip

    Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help?

    Obesity drugs like Wegovy are proving useful in many diseases. Polycystic ovary syndrome, a chronic condition that can cause infertility, may be one.

  • A sign reading Novo Nordisk is seen on the side of a building.
    Image attribution tooltip
    Victor Golmer via Getty Images
    Image attribution tooltip

    Novo nixes trial of blood pressure drug it bought in $1.3B deal

    The failure of a Phase 3 study led the Wegovy maker to take an accounting charge that will hit its operating profit growth this year.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Zealand hauls in $1B off obesity drug data; Curie.bio zeroes in on Series A’s

    Zealand capitalized on a stock surge following the release of early study results. Elsewhere, U.S. regulators rejected an AbbVie medicine and another well-funded AI drug discovery startup emerged. 

  • Faye Feller, executive vice president, chief medical officer, Geron
    Image attribution tooltip
    Permission granted by Geron
    Image attribution tooltip

    After 33 years, Geron’s first approval marks a turn in Nobel-winning science

    The decades-long story of how a novel type of blood cancer drug went from a scientific idea to an approved product.

  • An image of a neural cell, colored red, is seen on a black background.
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Wave, with new data, plots path forward for Huntington’s drug

    The company plans to make a case to regulators for a new accelerated approval pathway. But investors didn't seem as hopeful, sending shares down by double digits.

  • An illustration of DNA against a blue abstract background
    Image attribution tooltip
    Olena_T via Getty Images
    Image attribution tooltip
    Emerging biotech

    Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine

    The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.

  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    aprott via Getty Images
    Image attribution tooltip

    Novo to spend $4B on US plant, adding to obesity drug production push

    The planned facility in North Carolina is Novo’s latest multibillion-dollar investment in the manufacturing of weight loss drugs, demand for which continues to outstrip supply.

  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Ivan-Balvan via Getty Images
    Image attribution tooltip

    Alnylam says heart drug succeeds in closely watched study

    Positive results from a Phase 3 trial of vutrisiran in transthyretin amyloidosis cardiomyopathy come eight months after the FDA rejected another medicine Alnylam developed for the condition.

    Updated June 24, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Obesity drugs from Altimmune, Hengrui show potential; Lilly details Zepbound sleep apnea data

    The American Diabetes Association’s annual meeting provided a forum for early trial results on several would-be weight loss drug competitors.

  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo fills in positive picture for preventive hemophilia drug

    Phase 3 trial results should support an approval application for the drug, which analysts view as a competitor to Roche’s blockbuster medicine Hemlibra.

  • A photo of FDA CBER Director Peter Marks delivering remarks at a public workshop on March 3, 2020.
    Image attribution tooltip
    Ermath, Michael. (2020). "Individualized Therapies Workshop" [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    Duchenne approval exposes FDA rift over Sarepta gene therapy

    Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote.

    FDA
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Sarepta Duchenne gene therapy wins broader use from FDA

    The approval makes Elevidys available to most Duchenne patients at least 4 years of age, despite mixed trial results that have led to skepticism about its effectiveness. 

    Updated June 21, 2024
    FDA
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Twice-yearly shots of Gilead HIV drug effective in large prevention study

    Researchers recommended Gilead end testing early as lenacapavir proved 100% effective in protecting cisgender women in the Phase 3 trial.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

    A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.

  • A person with obesity prepares a drug for injection.
    Image attribution tooltip
    iStock / Getty Images Plus via Getty Images
    Image attribution tooltip
    Obesity drugs

    Obesity drug from Zealand shows potential in early trial

    Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.

  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    whitehoune via Getty Images
    Image attribution tooltip

    FDA lifts hold on PTC Huntington’s disease trial

    The agency has lifted a partial trial suspension based on one-year data showing PTC’s pill suppressed a key protein associated with the disorder.

  • Amazon Pharmacy
    Image attribution tooltip
    Courtesy of Amazon
    Image attribution tooltip

    Amazon expands drug subscription program to Medicare members

    RxPass, which fills prescriptions for generic drugs, is now available to more than 50 million Medicare members after Amazon brought it into compliance with the insurance program’s regulatory standards.

  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck wins FDA OK for vaccine rival to Pfizer’s pneumococcal shot

    The new vaccine, which Merck will sell as Capvaxive, will compete with Pfizer’s blockbuster Prevnar franchise.

  • Left: Josh Lehrer, CEO of Marea Therapeutics, right: Ethan Weiss, chief scientific officer of Marea Therapeutics
    Image attribution tooltip
    Permission granted by Marea Therapeutics
    Image attribution tooltip
    Emerging biotech

    Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.

    With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address. 

  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Intra-Cellular depression drug succeeds in second late-stage study

    The results position the company to unlock what’s believed to be a multibillion-dollar sales opportunity for Caplyta, which is already used to treat schizophrenia and bipolar disorder. 

  • Two researchers in safety goggles and lab coats work in a lab.
    Image attribution tooltip
    Permission granted by Kevin Trimmer/Ascidian Therapeutics
    Image attribution tooltip

    Roche partners with RNA editing biotech Ascidian

    While the Swiss pharma recently pruned its neurology drug pipeline, it has shown interest in the possibilities of RNA-focused approaches like what Ascidian is exploring.

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

    Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.